Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03238677 · ClinicalTrials.gov registry record · NA

Treating Childhood Apraxia of Speech

A NA study, sponsored by Syracuse University.

Completed
Registry status
NA
Development phase
56
Enrollment target

NCT03238677: Completed NA study, sponsored by Syracuse University.

NCT03238677 is a NA study that has completed, run by Syracuse University. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03238677, a NA study, has completed, sponsored by Syracuse University.

COMPLETED
Registry status
NA
Development phase
56 participants
Enrollment target

Study Summary

The study will test two modifications to speech therapy for 40 school-age children with childhood apraxia of speech to determine how to improve treatment outcomes. The study will compare treatment that includes real-time visual feedback of the tongue during speech using ultrasound vs traditional therapy that does not include ultrasound visual feedback. Additionally, some children will be treated with a traditional schedule of 2 sessions per week, whereas others will be provided with treatment that begins with intensive training (10 hours of therapy in one week) and progresses to a more distributed treatment schedule.

Primary Outcome

Percent consonants correct for target sounds: The primary outcome measure was percent correct for each participant's target sound-positions in untreated phrase. Participants imitated 20 pre-recorded phrases, each containing the target sound pattern 2 times per stimulus (e.g., for /l/ onset, "leave the location"), resulting in 40 attempts at each sound-position. For each session, 3 transcribers independently transcribed in Phon software (Hedlund \& Rose, 2022) and accuracy was averaged across tra

Interventions

  • BEHAVIORAL Biofeedback
  • BEHAVIORAL Speech Motor Chaining without Biofeedback
  • BEHAVIORAL Distributed Practice
  • BEHAVIORAL Massed --> Distributed Practice

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2017-08-01
Est. Completion 2022-06-07
Phase NA
Syracuse University

31 total trials

What the finished NCT03238677 record still lists

NCT03238677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 4 interventions - of which Biofeedback is the first listed.

NCT03238677 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03238677 about?

NCT03238677 is a clinical study titled "Treating Childhood Apraxia of Speech". The study will test two modifications to speech therapy for 40 school-age children with childhood apraxia of speech to determine how to improve treatment outcomes. The study will compare treatment that includes real-time visual feedback of the tongue during speech using ultrasound vs traditional the...

What is the current status of trial NCT03238677?

This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2017-08-01. Estimated completion is 2022-06-07.

What interventions are being tested in trial NCT03238677?

The interventions under investigation include: Biofeedback (BEHAVIORAL), Speech Motor Chaining without Biofeedback (BEHAVIORAL), Distributed Practice (BEHAVIORAL), Massed --> Distributed Practice (BEHAVIORAL).

Who is sponsoring clinical trial NCT03238677?

This trial is sponsored by Syracuse University, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03238677's enrollment target sits among peer trials

56 1262nd of 2000 higher than 737 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03238677, the US trial registry maintained by the National Library of Medicine. NCT03238677 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.